Marq Marquez’s Post

In an exclusive interview with BioPharma APAC, Ti Hwei How, Vice President of International Oncology & Market Access at AstraZeneca, sheds light on the growing burden of lung cancer in low- and middle-income countries (LMICs). With lung cancer accounting for one in five cancer deaths globally, How discusses the need for targeted approaches, early detection, and global collaboration to address disparities in care and outcomes. From leveraging cutting-edge AI-assisted diagnostics to forming partnerships with governments and healthcare systems, AstraZeneca’s initiatives aim to transform the standard of lung cancer care across LMICs. #LungCancerAwareness #AstraZenecaLeadership #GlobalHealthEquity #LMICHealthcare #OncologyInnovation #AIinHealthcare #CancerCareSolutions #EarlyCancerDetection #GlobalCollaboration #HealthcarePartnerships

In 2022, around 2.7 million people in the European Union were diagnosed with cancer, and 1.3 million lost their lives to the disease (ECIS Factsheet 2022). In an interview with The Parliament, Dr. Kandeepan Ganeshalingam, Vice President Oncology International Medical Affairs at Pfizer, discusses the significant advances in cancer treatment, the ongoing challenges and unmet needs, and Pfizer’s commitment to bringing new oncology medicines to patients in Europe and around the world. At Pfizer, our vision is of a world where people with cancer live better and longer lives. To fully unlock the potential of innovative treatments, industry, policymakers, and regulators must work together to ensure breakthroughs reach patients in a timely manner. Read the full interview here: https://lnkd.in/epBJ5Jb7 #Oncology #MedicalInnovation #EUBeatingCancerPlan

🚨 Breaking News in Cancer Research! 🚨 Roche's phase III SKYSCRAPER-01 trial has revealed that the combination of tiragolumab and Tecentriq does not provide an overall survival benefit for patients with PD-L1-high non-small cell lung cancer (NSCLC). 🔍 Key Insights: - While the primary endpoint was not met, there may still be potential in specific patient subgroups. - Future analyses could uncover secondary benefits beyond overall survival metrics. - Roche remains committed to optimizing treatment protocols and advancing cancer care. The safety profile of the combination therapy was consistent with previous findings, showing no new adverse effects. Roche plans to leverage insights from this study to refine therapeutic strategies and enhance patient outcomes. Stay tuned for detailed results at a medical conference in 2025! For more information on this significant development, click on the link below! #CancerResearch #ClinicalResearches #ClinicalTrials #InnovationInHealthcare #NSCLC #PharmaceuticalCompanies #Roche #MarketAccess #MarketAccessToday

New Hope for Lung Cancer Patients: Tagrisso Approved for Stage III EGFR-Mutated NSCLC In a significant advancement for lung cancer treatment, the FDA has approved AstraZeneca's Tagrisso (osimertinib) for adult patients battling unresectable, Stage III EGFR-mutated non-small cell lung cancer (NSCLC). This decision follows a Priority Review based on promising data from the LAURA Phase III trial, showcasing the drug’s efficacy in patients whose disease has not progressed after undergoing platinum-based chemoradiation therapy. Key Highlights from the LAURA Trial • Remarkable Efficacy: Tagrisso showed an 84% reduction in the risk of disease progression or death compared to placebo, translating to a median progression-free survival (PFS) of 39.1 months versus just 5.6 months for those on placebo. • Wide Impact: This approval is pivotal as 15% of NSCLC patients in the U.S. have EGFR mutations, and nearly 20% of these have unresectable tumors, representing a significant unmet need in targeted therapy. The Journey Ahead Tagrisso, a third-generation EGFR tyrosine kinase inhibitor, has already been a game-changer in various stages of EGFRm NSCLC, and its approval for Stage III adds to its growing profile. The drug’s safety and tolerability align with its established reputation, with no new safety concerns reported during the trial. AstraZeneca’s commitment to advancing lung cancer treatment doesn’t stop here. Tagrisso is under evaluation for further indications globally, and the company is actively researching ways to combat resistance mechanisms to enhance patient outcomes. 📊 GlobalData analysis from Patent Analytics tool shows the key players with publications related to “Treating Non-Small Cell Lung Cancer (NSCLC)”.   ⚡ Connect with us today to explore the endless possibilities and propel your business forward! 📧 [email protected] or ☎ explore more at our contact page: https://lnkd.in/ggfMtshS #LungCancerAwareness #EGFRMutations #Tagrisso #CancerTreatment #NSCLC #TargetedTherapy #ClinicalTrials #Oncology #EarlyDetection

Cancer is one of the most complex and dynamic human diseases. Although considerable advances have been made to bring novel oncology medicines to patients, the reality is that unlocking disease biology and translating that into treatments remains hard. More than two decades ago, some radical thinking and bold science pioneered the immuno-oncology revolution, and it showed us how we can unlock immune system biology to treat cancer to great effect. But since the first wave of treatments that followed, we as an industry haven’t delivered on the promised next wave of immunotherapy and cytokine-based treatments, something that is desperately needed as current immuno-oncology (I-O) response rates have plateaued around 30%.

This is an informative overview of the American Cancer Society Cancer Action Network (ACS CAN)'s consensus recommendations for how the US healthcare systems can implement pharmacogenomics testing in cancer care with an eye toward equity and overcoming adoption barriers. #pgx #pharmacogenomics #pharmacovigilance #precisionmedicine #precisiononcology #healthcareequity

#Smallcelllungcancer #Newdrug #Promising The FDA just approved a new and unique treatment for advanced lung cancer that prolongs life significantly and works in unique ways to address cancer cells. Important read!

The longstanding one-size-fits-all mentality of measuring efficacy in oncology trials does not always account for the varied experiences of people living with cancer. Awny Farajallah, MD, FACP, Chief Medical Officer, says that as cancer continues to evolve, so should our approach to measuring patient outcomes. Read why it's time to rethink clinical trials in STAT: https://lnkd.in/gf-FZzvH

Do cutting-edge CAR-T-cell therapies cause cancer? What the data say - story in Nature What I say is that in these very very rare instances we need more data to go from correlation to causation.

This week we announced the positive results from our model-development study for our next-generation test. In the study, Immunovia’s next-generation test demonstrated specificity of 98 percent and sensitivity of 75 percent in detecting early stage (1 and 2) pancreatic ductal adenocarcinoma (PDAC), a very aggressive and the most common form of pancreatic cancer. The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.    “Pancreatic cancer is a brutal and lethal cancer. People at risk for pancreatic cancer need a simple, fast, and easy blood test to detect cancer early. We are very excited about the potential of our test to meet this need and increase survival rates for these patients”, says Jeff Borcherding, CEO and President of Immunovia. Immunovia will now move to a second phase of the model development study, expected to be completed in 6 – 8 weeks, in which it will conduct additional statistical analyses to refine and assess the robustness of the test model.   Read more about the news on the link below.   #earlydetection #pancreaticcancer